Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: A systematic review and meta-analysis

Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: A systematic review and meta-analysis

Forfattere
Kobayashi, T. Matsuyama, T. Takeuchi, M. Ito, S.
Årstall
2016
Tidsskrift
Reproductive Toxicology
Volum
65
Sider
170-178
To obtain the risk estimates of autism spectrum disorder (ASD) in the offspring exposed to serotonin reuptake inhibitors (SSRI) in utero, we performed systematic review and meta-analysis of relevant studies. Five case-control and three cohort studies were eligible for the analysis. The SSRI group had significantly higher risk of ASD than the SSRI non-exposed group (pooled OR 1.45, 95% CI 1.15-1.82). In the subgroup analyses, however, the risk of ASD was similar between the SSRI group and other antidepressants group (pooled OR 1.14, 95% CI 0.67-1.96). Furthermore, when the analysis was confined to those born to the women with psychiatric disorders, the SSRI group did not show an increased ASD risk (pooled OR 0.96, 95% CI 0.57-1.63) compared to non-exposed groups. In conclusion, SSRI use in pregnancy is associated with an increased risk of ASD in the offspring, but maternal psychiatric condition is a major confounding factor. Copyright © 2016 Elsevier Inc.

Oversett med Google Translate
-
Tiltaksnivå

Behandling og hjelpetiltak

Tema

Psykiske vansker og lidelser

Autismespekter

Biologiske risikofaktorer, sykdommer og symptomer

Gravide (inkl. tenåringsmødre)

Tiltak

Medikamentell behandling

Antidepressiva

Psykososiale hjelpetiltak

Tiltak rettet mot gravide og barselkvinner

Aldersgruppe

Sped- og småbarn (0-2 år)

Mer informasjon
Leter du etter mer informasjon om temaet? Trykk på lenkene nedenfor for å søke i PsykTestBarn og Håndboka for barn og unges psykiske helse.